This topic contains a solution. Click here to go to the answer

Author Question: A patient receiving intravenous heparin (Liquaemin) therapy receives a first dose of warfarin ... (Read 63 times)

Mr3Hunna

  • Hero Member
  • *****
  • Posts: 536
A patient receiving intravenous heparin (Liquaemin) therapy receives a first dose of warfarin (Coumadin). The patient asks the health care provider when the heparin drip will be discontin-ued.
 
  Review the following responses and select the one which is accurate.
  a. Immediately
  b. In 1-2 hours
  c. In 12-24 hours
  d. In 48-72 hours

Question 2

Which of the following conditions would contraindicate the use of warfarin (Coumadin) therapy in a patient?
 
  a. Deep vein thrombosis
  b. Pulmonary embolism
  c. Pregnancy
  d. Hypercoagulability



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

rosiehomeworddo

  • Sr. Member
  • ****
  • Posts: 306
Answer to Question 1

ANS: D
Although the anticoagulant effects of warfarin begin in 8-12 hours, its peak effects do not occur for 48-72 hours. This is because the drug has no effect on existing clotting factors, which take from 6 to 60 hours to decay in the blood stream.

Answer to Question 2

ANS: C
Warfarin is contraindicated for use during pregnancy and lactation.




Mr3Hunna

  • Member
  • Posts: 536
Reply 2 on: Jul 23, 2018
Thanks for the timely response, appreciate it


ghepp

  • Member
  • Posts: 361
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

The familiar sounds of your heart are made by the heart's valves as they open and close.

Did you know?

Illness; diuretics; laxative abuse; hot weather; exercise; sweating; caffeine; alcoholic beverages; starvation diets; inadequate carbohydrate consumption; and diets high in protein, salt, or fiber can cause people to become dehydrated.

Did you know?

Alcohol acts as a diuretic. Eight ounces of water is needed to metabolize just 1 ounce of alcohol.

Did you know?

Computer programs are available that crosscheck a new drug's possible trade name with all other trade names currently available. These programs detect dangerous similarities between names and alert the manufacturer of the drug.

Did you know?

This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.

For a complete list of videos, visit our video library